
A popular investment strategy among savvy investors is to diversify their portfolio by investing in growth stocks with strong fundamentals from various industries. Growth stocks in burgeoning industries are typically in their early stages, some possessing great long-term prospects. Here, we have two such growth stocks that have received a consensus "strong buy" rating from Wall Street analysts.
The first one is Skye Bioscience (SKYE), whose stock has soared 427.2% year-to-date, massively outperforming the S&P 500 Index’s ($SPX) gain of 10.6%. It is a biopharmaceutical company exploring the potential of cannabinoid-based therapeutics.